Johnson & Johnson Expects Growth In
Products, Medical Devices Through 2012
Diversified health care products company Johnson & Johnson expects sharp growth
from its medical device units over the next several years, with orthopedic and
surgical care products leading the way.
The company expects an average of 6 percent annual growth in revenue from the
surgical care unit over the next 4 years, reaching $40 billion in 2012.
Orthopedic products, many of which are used to fix damaged or diseased joints,
will get a 9 percent annual boost to $48 billion, according to projections.
Sheri McCoy, worldwide chairwoman for the surgical care unit, said the company
is focusing on developing less-invasive surgical products and looking to
emerging markets to help fuel growth. More than half of surgical sales now come
from outside the U.S., she said.
Michael Mahoney, the group chairman of Depuy, which makes spine, hip and knee
products, said the unit gets more than 40 percent of its revenue from outside
the U.S. and claims the No. 2 spot in the global market, while retaining the top
spot in the U.S. market.
Brazil, Russia, India, and China had record growth last year, and the company is
making investments to build on that momentum.
The company has been introducing a range of new product platforms that include
more durable materials and instruments for minimally invasive surgery. Those are
both necessary to stay on top, as patients in several segments are increasingly
younger, including hip replacement patients, who are demanding better implants
and less-invasive techniques.
The Depuy unit was the largest revenue contributor out of the medical device
division, accounting for $4.59 billion in sales in 2007. Overall, medical device
sales are the second largest revenue driver for the company, behind
Solvay Advanced Polymers Commissions New PEEK Plant
Solvay Advanced Polymers, makers of more plastics with more performance has
announced that it has commissioned its new commercial PEEK (polyetheretherketone)
facility at its site in Panoli, India. The new facility is now in its start-up
phase and is running initial commercial production. The plant is capable of
producing 500 metric tons annually, and is scalable in design to double capacity
to meet demand for Solvay Advanced Polymers’ KetaSpire® PEEK and AvaSpire®
modified PEEK products.
With this the company has completed a significant step in its strategic entrance
into the PEEK market. In the past 18 months, Solvay Advanced Polymers has been
seeding and specifying its KetaSpire PEEK and AvaSpire modified PEEK into a
range of markets and applications from its semi-commercial facility. The new
commercial facility in Panoli will now support and expand upon those
KetaSpire PEEK and AvaSpire modified PEEK are highly-prized ultra polymers that
offer design engineers best-in-class chemical resistance and mechanical
properties, including strength, stiffness and ease of processing. This
combination of performance attributes makes PEEK an ideal polymer for
applications in aerospace, automotive, friction and wear components, healthcare,
oil exploration and production, and semi-conductors, among others. KetaSpire
PEEK is also available in film form for specialized applications.